MIRA PHARMACEUTICALS, INC. 8-K

What Happened

• On July 10, 2026 MIRA Pharmaceuticals filed an 8-K and issued a press release reporting positive preclinical study results for optimized oral formulations of MIRA-55, the company’s non‑opioid candidate for chronic inflammatory pain. The company selected a lead oral formulation that demonstrated favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into both brain and liver following oral dosing. An intravenous reference arm was included to characterize absolute oral bioavailability.

Key Details

• Date filed: July 10, 2026 (8-K filing and press release).
• Lead formulation selected for: favorable oral bioavailability, sustained systemic exposure, and reproducible brain and liver distribution.
• Study design note: included an IV reference arm to quantify absolute oral bioavailability and support formulation selection.
• Prior/preclinical results referenced: oral MIRA-55 normalized pain and reduced inflammation in a validated inflammatory pain model (reported to outperform injected morphine); showed anxiolytic activity; did not produce THC‑like central nervous system effects; interacts with the cannabinoid system via a mechanism distinct from THC.

Why It Matters

• Positive preclinical pharmacokinetic data for an oral formulation strengthen MIRA‑55’s development profile by showing the drug achieves meaningful systemic levels and reaches tissues relevant to both central and peripheral pain mechanisms—important for a potential oral, non‑opioid chronic pain therapy.
• These results build on earlier efficacy and mechanistic preclinical findings cited by the company, potentially supporting future clinical development plans (e.g., IND-enabling studies and human trials).
• Important caveat for investors: these are preclinical findings reported via press release/8-K; the filing does not report clinical trial starts, timelines, regulatory approvals, or financial impacts. Further studies and regulatory steps are required before any potential commercial or revenue outcomes.